Celldex Therapeutics, Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.7M | $6.8M | $5.5M | $3.6M | $4.1M | $11.2M | $9.3M | $46.8M |
| Cost of Revenue | $700.0K | $1.6M | — | — | — | — | — | — |
| Gross Profit | $12.0M | $5.2M | — | — | — | — | — | — |
| Gross Margin | 94.5% | 76.4% | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $96.2M | $102.7M | $100.2M | $104.4M | $67.4M | $47.4M | $32.4M | $27.7M |
| SG&A Expense | $25.0M | $36.0M | $33.8M | $20.6M | $14.8M | $10.0M | $9.2M | $10.4M |
| Operating Income | $-121.5M | $-132.9M | $-129.5M | $-122.4M | $-81.4M | $-58.1M | $-43.4M | $-6.5M |
| Operating Margin | -953.7% | -1,958.7% | -2,363.9% | -3,414.1% | -1,981.1% | -518.5% | -468.4% | -13.8% |
| Interest Expense | — | — | — | — | $927.0K | $1.6M | $1.8M | $1.3M |
| Pretax Income | $-117.3M | $-128.5M | $-127.2M | — | — | — | $-44.8M | $-2.5M |
| Income Tax Expense | $-24.3M | — | — | — | $0 | $0 | — | — |
| Net Income | $-93.0M | $-128.5M | $-127.2M | $-118.1M | $-81.6M | $-59.1M | $-44.8M | $-2.5M |
| Net Margin | -730.1% | -1,894.0% | -2,321.1% | -3,292.8% | -1,983.7% | -527.8% | -483.5% | -5.4% |
| EPS (Basic) | $-0.01 | $-0.01 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $-0.01 | $-0.01 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 19.08B | 248.99B | 203.88B | 185.10B | 184.38B | 132.97B | 81.61B | 65.84B |
| Shares Outstanding (Diluted) | 19.08B | 248.99B | 203.88B | 185.10B | 184.38B | 132.97B | 81.61B | 65.84B |
| Dividends Per Share | — | — | — | — | — | — | — | — |